Why is Alivus Life falling/rising?

As of 17-Nov, Alivus Life Sciences Ltd is experiencing a price increase, currently at 945.40, which reflects a rise of 41.05 or 4.54%. The stock has shown positive momentum, gaining 4.67% over the last two days and outperforming its sector by 4.26% today. Despite this recent uptick, the stock has underperformed over the past year, with a return of -11.99%, while its profits have increased by 25.2%. The company maintains a high management efficiency with a return on equity (ROE) of 18.73% and a low debt-to-equity ratio, which contributes positively to its valuation. However, the stock is trading at a premium compared to its peers, and its long-term growth prospects appear weak, with net sales and operating profit growing at only 4.84% and 2.21% annually over the last five years, respectively.
In the broader market context, Alivus Life's short-term performance has outpaced the Sensex, which has returned 1.69% over the past week and 1.19% over the past month, while Alivus has returned 2.30% and 2.11% in the same periods. Despite this positive short-term trend, the stock's year-to-date performance remains concerning, with a decline of 4.41% compared to the Sensex's gain of 8.72%. The stock's liquidity is adequate for trading, but a significant drop in delivery volume indicates a potential decline in investor interest. Overall, while recent gains are encouraging, the company's long-term growth challenges and underperformance relative to the broader market may weigh on future price movements.